Quest Diagnostics Pays 13m To Settle Allegations Tied To Giants Ticket Perks

Quest Diagnostics Inc. paid $13.01M to settle allegations of violating anti-kickback laws by offering perks like Giants tickets for referrals. The company denies wrongdoing but agreed to a settlement to resolve the matter. The case involved Medicare and Medicaid referrals in NJ and NY, with whistleblowers receiving $2.47M.

Original reporting
Published Nov 9, 2026, 5:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 9:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Quest Diagnostics Pays 13m To Settle Allegations Tied To Giants Ticket Perks — source image
Decision brief

The 30-second read

$DGXBearishLow
01

Why it matters

The $13M settlement and five‑year Corporate Integrity Agreement introduce new compliance costs and oversight, which could affect earnings and investor sentiment.

02

Market read

First disclosure of a legal settlement that may pressure DGX stock and signal heightened regulatory focus on health‑care service firms.

03

What to watch

Potential for the Corporate Integrity Agreement to improve long‑term governance and reduce future penalties.

Relevance 7/10Novelty 8/10Timing: immediate

Background

Quest Diagnostics, a major provider of diagnostic testing services, faced federal anti‑kickback allegations related to free tickets for New York Giants games.

Company-level read

Ticker impact

$DGXBearishHigh confidence
Context

Quest Diagnostics settled a $13M anti‑kickback lawsuit, the first public disclosure of the enforcement action.

Expected impact

likely downside as market prices in the settlement and regulatory scrutiny

Evidence & confidence

New enforcement action, cash outflow, and reputational risk typically depress stock price in the short term.

Market effects

May raise compliance scrutiny for other lab testing firms and health‑care service providers.

Limited to U.S. health‑care sector; no broader regional effect.

Minimal global impact beyond U.S. healthcare compliance environment.

Counterpoint

The settlement amount is modest relative to Quest's size; the market may have already priced in the risk.

Key entities

  • Quest Diagnostics Inc.

    U.S. diagnostic testing provider that settled the anti‑kickback case.

  • U.S. Attorney's Office for the District of New Jersey

    Prosecutor that announced the settlement.

Related articles

$DGXLow

Quest Diagnostics Pays $13 Million to Settle Kickback Allegations Involving New York Giants Tickets

Quest Diagnostics will pay $13M to settle allegations of illegal kickbacks, including New York Giants tickets, to healthcare providers. The U.S. Attorney's Office claims the company violated the Anti-Kickback Statute from 2013 to 2022, offering perks in exchange for business referrals. Quest denies wrongdoing but agreed to a settlement and a 5-year compliance agreement.

$DGXLow

Quest Diagnostics pays more than $13M to settle alleged kickback scheme, federal prosecutors say

Quest Diagnostics agreed to pay $13M to settle allegations of a kickback scheme involving gifts to hospital executives, including New York Giants game tickets, according to federal prosecutors. The scheme allegedly lasted from 2013 to 2022, with Quest billing government-funded medical plans. The company will also face five years of auditing. Quest reported $11B in 2025 revenue, up 7%.

$DGXLow

Quest Diagnostics pays $13M to settle kickback allegations involving NY Giants tickets

Quest Diagnostics agreed to pay $13M to settle allegations of providing illegal kickbacks, including NY Giants tickets, to healthcare providers for referrals, according to the U.S. Attorney’s Office of New Jersey. The settlement resolves claims of violating the Anti-Kickback Statute and submitting false claims to Medicare and Medicaid. Quest denies wrongdoing but agreed to the settlement to resolve the matter.

$DGXLow

Quest Diagnostics pays more than $13 million to settle allegations of illegal kickbacks involving Giants tickets, VIP events

Quest Diagnostics Inc. paid $13,014,576 plus interest to settle federal allegations of illegal kickbacks involving free New York Giants tickets and VIP events to induce patient referrals. The company violated the Anti-Kickback Statute and submitted false claims to Medicare and Medicaid programs, according to the U.S. Attorney’s Office. Quest also entered a five-year Corporate Integrity Agreement with HHS-OIG. Whistleblowers will receive nearly $2.5 million.

$LHMed

Labcorp, Quest urge RESULTS Act passage as lab payment cuts loom

Labcorp and Quest Diagnostics warn of revenue impacts from upcoming Medicare and Medicaid reimbursement cuts starting in 2027. Labcorp expects a $125 million hit, while Quest estimates a 1% revenue reduction in 2026. Both companies advocate for the passage of the RESULTS Act to reform the payment rate-setting process, citing concerns over patient access and lab viability.

$DGXMed

New York State Data Exposed Following Quest Diagnostic Breach

Quest Diagnostics disclosed a data breach in its Quanum Lab Services Manager system, exposing patient records, including names, Social Security numbers, and medical information. The breach was contained, but the exact number of affected individuals is still under investigation. Quest will notify impacted patients and offer identity theft monitoring services. The company serves 1 in 3 American adults annually.